Session » (0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I
-
Abstract Number: 0229
Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout
-
Abstract Number: 0230
Looking Beyond Infections in Job Syndrome: Peripheral Calcium Pyrophosphate Deposition Disease in a Cohort of Patients with Job Syndrome
-
Abstract Number: 0231
Febuxostat Dose Requirement for Achieving Target Serum Urate Levels According to Renal Function: A Retrospective Cohort Study
-
Abstract Number: 0232
Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USA
-
Abstract Number: 0233
Impaired Anti-oxidant Function of HDL and Its Associated Protein, Paraoxonase-1, in Patients with Gout
-
Abstract Number: 0234
Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
-
Abstract Number: 0235
Fractures in Patients with Acute CPP Crystal Arthritis versus Matched Comparators in a Large Cohort Study
-
Abstract Number: 0236
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
-
Abstract Number: 0237
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
-
Abstract Number: 0238
Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature
-
Abstract Number: 0239
Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database
-
Abstract Number: 0240
Gout: A Gateway to Chronic Opioid Use?
-
Abstract Number: 0241
Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial
-
Abstract Number: 0242
Venous Thromboembolism in Patients with Gout in the US
-
Abstract Number: 0243
Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center
-
Abstract Number: 0244
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
-
Abstract Number: 0245
Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout
-
Abstract Number: 0246
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
-
Abstract Number: 0247
Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States
-
Abstract Number: 0248
In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout
-
Abstract Number: 0249
Comorbidities of Gout: Results from the Korean National Health and Nutrition Examination Survey